CD4 T-helper responses to the anaplastic lymphoma kinase (ALK) protein in patients with ALK-positive anaplastic large-cell lymphoma

被引:37
作者
Ait-Tahar, Kamel
Barnardo, Martin C. N.
Pulford, Karen
机构
[1] John Radcliffe Hosp, Nuffield Dept Clin Lab Sci, Leukemia Res Fund Lymphoma Antigens Grp, Leukemia Res Fund Immunodiagnost Unit, Oxford OX3 9DU, England
[2] Churchill Hosp, Oxford Transplant Ctr, Oxford OX3 7LJ, England
关键词
D O I
10.1158/0008-5472.CAN-06-4427
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We have previously shown both Immoral and CTL responses to anaplastic lymphoma kinase (ALK) in patients with ALK-positive anaplastic large-cell lymphoma (ALCL). However, because CD4(+) T-helper (Th) cells also play a vital role in developing and maintaining tumor immunity, we investigated the presence of a CD4(+) Th response in ALK-positive ALCL. Using an IFN-gamma ELISPOT assay, we identified two ALK-derived DRB1-restricted 24-mer promiscuous peptides, ALK1(278-301) and ALK2(233-256), as being immunogenic in six ALK-positive ALCL patients but not in two ALK-negative ALCL patients or five normal subjects. A significant interleukin-4 response to the ALK peptides was detected in only one ALK-positive patient. CD4(+) Th cell lines lysed ALK-positive ALCL cell lines in a MHC class II-restricted manner. This first report of a CD4(+) Th response to ALK provides valuable information for developing future immunotherapeutic options for ALK-positive ALCL patients who fail to respond well to conventional therapies.
引用
收藏
页码:1898 / 1901
页数:4
相关论文
共 20 条
[1]   B and CTL responses to the ALK protein in patients with ALK-positive ALCL [J].
Ait-Taharl, K ;
Cerundolo, V ;
Banham, AH ;
Hatton, C ;
Blanchard, T ;
Kusec, R ;
Becker, M ;
Smith, GL ;
Pulford, K .
INTERNATIONAL JOURNAL OF CANCER, 2006, 118 (03) :688-695
[2]   Specific human cellular immunity to bcr-abl oncogene-derived peptides [J].
Bocchia, M ;
Korontsvit, T ;
Xu, Q ;
Mackinnon, S ;
Yang, SY ;
Sette, A ;
Scheinberg, DA .
BLOOD, 1996, 87 (09) :3587-3592
[3]   ALK-positive anaplastic large-cell lymphoma: strong T and B anti-tumour responses may cause hypocellular aspects of lymph nodes mimicking inflammatory lesions [J].
Borisch, B ;
Yerly, S ;
Cerato, C ;
Schwaller, J ;
Wacker, P ;
Ozsahin, AH ;
Brousse, N ;
Hoessli, DC .
EUROPEAN JOURNAL OF HAEMATOLOGY, 2003, 71 (04) :243-249
[4]   Human CD4+ effector memory T cells persisting in the microenvironment of lung cancer xenografts are activated by local delivery of IL-12 to proliferate, produce IFN-γ, and eradicate tumor cells [J].
Broderick, L ;
Yokota, SJ ;
Reineke, J ;
Mathiowitz, E ;
Stewart, CC ;
Barcos, M ;
Kelleher, RJ ;
Bankert, RB .
JOURNAL OF IMMUNOLOGY, 2005, 174 (02) :898-906
[5]   Phototyping: Comprehensive DNA typing for HLA-A, B, C, DRB1, DRB3, DRB4, DRB5 & DQB1 by PCR with 144 primer mixes utilizing sequence-specific primers (PCR-SSP) [J].
Bunce, M ;
ONeill, CM ;
Barnardo, MCNM ;
Krausa, P ;
Browning, MJ ;
Morris, PJ ;
Welsh, KI .
TISSUE ANTIGENS, 1995, 46 (05) :355-367
[6]  
DELSOL G, 2001, ANAPLASTIC LARGE CEL, P230
[7]   Immunization with a HER-2/neu helper peptide generates HER-2/neu CD8 T-cell immunity in cancer patients [J].
Knutson, KL ;
Schiffman, K ;
Disis, ML .
JOURNAL OF CLINICAL INVESTIGATION, 2001, 107 (04) :477-484
[8]   T helper 2-dominant antilymphoma immune response is associated with fatal outcome [J].
Lee, PP ;
Zeng, DF ;
McCaulay, AE ;
Chen, YF ;
Geiler, C ;
Umetsu, DT ;
Chao, NJ .
BLOOD, 1997, 90 (04) :1611-1617
[9]   CD4+ T lymphocytes:: A critical component of antitumor immunity [J].
Ostrand-Rosenberg, S .
CANCER INVESTIGATION, 2005, 23 (05) :413-419
[10]   ALK as a novel lymphoma-associated tumor antigen: identification of 2 HLA-A2.1-restricted CD8+T-cell epitopes [J].
Passoni, L ;
Scardino, A ;
Bertazzoli, C ;
Gallo, B ;
Coluccia, AML ;
Lemonnier, FA ;
Kosmatopoulos, K ;
Gambacorti-Passerini, C .
BLOOD, 2002, 99 (06) :2100-2106